PURPOSE: The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of sequential transarterial chemoembolization (TACE) for patients with unresectable advanced hepatocellular carcinoma (HCC). METHODS: Twenty-one consecutive patients with unresectable T3 and T4 HCC were treated by sequential TACE (median time interval between treatments 7 weeks) up to six times with an emulsion of lipiodol, epirubicin, and cisplatin. All TACE procedures were performed as unilobar or whole-liver chemoembolization. RESULTS: An average of 3.9 TACE procedures were performed per patient. One primary and two secondary technical failures occurred. No procedural death was observed. After exclusion of the patient with the primary technical failure and 3 patients with extrahepatic disease, the survival rates for the remaining 17 patients at 6, 12, 18, and 24 months were 70.6%, 52.9%, 44.1%, and 33.1%, respectively. CONCLUSION: Sequential TACE is a safe procedure in patients with unresectable advanced HCC and feasible in most cases. It seems to prolong the survival time compared with historical series of untreated patients.
PURPOSE: The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of sequential transarterial chemoembolization (TACE) for patients with unresectable advanced hepatocellular carcinoma (HCC). METHODS: Twenty-one consecutive patients with unresectable T3 and T4 HCC were treated by sequential TACE (median time interval between treatments 7 weeks) up to six times with an emulsion of lipiodol, epirubicin, and cisplatin. All TACE procedures were performed as unilobar or whole-liver chemoembolization. RESULTS: An average of 3.9 TACE procedures were performed per patient. One primary and two secondary technical failures occurred. No procedural death was observed. After exclusion of the patient with the primary technical failure and 3 patients with extrahepatic disease, the survival rates for the remaining 17 patients at 6, 12, 18, and 24 months were 70.6%, 52.9%, 44.1%, and 33.1%, respectively. CONCLUSION: Sequential TACE is a safe procedure in patients with unresectable advanced HCC and feasible in most cases. It seems to prolong the survival time compared with historical series of untreated patients.
Authors: Y Yumoto; K Jinno; K Tokuyama; Y Araki; T Ishimitsu; H Maeda; T Konno; S Iwamoto; K Ohnishi; K Okuda Journal: Radiology Date: 1985-01 Impact factor: 11.105
Authors: M Monden; J Okamura; M Sakon; M Gotoh; K Kobayashi; K Umeshita; T Yamada; C Kuroda; M Sakurai; T Mori Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333
Authors: T Livraghi; L Bolondi; S Lazzaroni; G Marin; A Morabito; G L Rapaccini; A Salmi; G Torzilli Journal: Cancer Date: 1992-02-15 Impact factor: 6.860
Authors: Jared A White; David T Redden; Mary Kate Bryant; David Dorn; Souheil Saddekni; Ahmed Kamel Abdel Aal; Jessica Zarzour; David Bolus; J Kevin Smith; Stephen Gray; Devin E Eckhoff; Derek A DuBay Journal: HPB (Oxford) Date: 2014-08-26 Impact factor: 3.647
Authors: Meredith C Mason; Nader N Massarweh; Aitua Salami; Mark A Sultenfuss; Daniel A Anaya Journal: HPB (Oxford) Date: 2015-09-16 Impact factor: 3.647
Authors: Thomas J Vogl; Patrik Schaefer; Thomas Lehnert; Nour-Eldin A Nour-Eldin; Hanns Ackermann; Emmanuel Mbalisike; Renate Hammerstingl; Katrin Eichler; Stephan Zangos; Nagy N N Naguib Journal: Eur Radiol Date: 2015-06-27 Impact factor: 5.315
Authors: Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742